cldx stock: Celldex Therapeutics Guide

CLDX (Celldex Therapeutics, Inc.)

This article explains cldx stock — the NASDAQ ticker for Celldex Therapeutics — covering company background, pipeline, financials, market data, governance, risks and where investors can follow updates. By the end you will know what cldx stock represents, where to find authoritative filings and how to monitor market information with Bitget tools.

Celldex Therapeutics (ticker symbol: CLDX) is a U.S. clinical‑stage biopharmaceutical company focused on immunotherapy and antibody‑based therapeutics. The term "cldx stock" refers to Celldex shares listed on the NASDAQ exchange and tracked by investors, analysts and financial news services. This guide is designed for beginners and intermediate readers who want a neutral, fact‑based overview of the company, its clinical pipeline, public financial profile and typical investment considerations.

As of Jan 28, 2026, according to public market trackers and company filings, cldx stock is categorized in the Biotechnology sector and is followed on major financial portals and regulatory filings. For trading access and portfolio monitoring, users can explore Bitget’s market tools and Bitget Wallet for secure custody and tracking.

Company overview

Celldex Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing targeted immunotherapies using therapeutic antibodies, antibody‑based constructs and immune modulators. The company’s model centers on advancing proprietary biologic candidates from preclinical stages through human clinical trials, often focusing on unmet needs in immune‑mediated diseases and oncology.

Key elements of Celldex’s business model:

• Research and development driven: primary investment in discovery, preclinical work and clinical trials.
• Clinical‑stage asset progression: value creation depends largely on clinical readouts, regulatory interactions and potential partnerships or licensing.
• Capital‑intensive operations: the company typically funds operations through public equity raises, debt facilities or collaborative deals.

Celldex’s scientific focus includes therapeutic antibodies, bispecific formats and immune system modulators intended to treat conditions ranging from allergic and inflammatory disorders to cancer indications.

Headquarters and corporate identity

Celldex Therapeutics is headquartered in Hampton, New Jersey, and is incorporated in the United States. The company trades under the ticker CLDX on the NASDAQ exchange and is commonly classified in the Biotechnology sector. Investors and analysts reference CLDX on financial portals and in SEC filings to follow corporate disclosures and financial performance.

History

Celldex was founded with the goal of translating antibody research into clinical candidates. Over time, the company has pursued a strategy of developing novel immunotherapies, progressing several molecules into clinical development and raising public capital to support trials. Notable milestones historically include the company’s IPO/listing on NASDAQ, progression of lead candidates into Phase 1–3 studies, and selective partnering or out‑licensing of programs as development strategies evolved.

Key historic points typically referenced by analysts and filings:

• Foundation and early discovery work establishing antibody platforms.
• NASDAQ listing and public‑company reporting cadence enabling capital markets access.
• Clinical trial initiations for lead candidates such as CDX‑0159 (Barzolvolimab) and CDX‑622 (example naming conventions used for investigational assets).

For precise foundational dates, IPO information and milestone press releases, review the company’s SEC filings and investor relations archives.

Pipeline and products

Celldex’s clinical value proposition is concentrated in a small number of clinical‑stage programs. The pipeline typically lists investigational therapeutic antibodies and immunomodulatory agents, each with a specific mechanism and target indication. Examples of programs that have been associated with Celldex include:

• Barzolvolimab (CDX‑0159): an anti‑KIT monoclonal antibody (example mechanism) being developed for mast cell–driven diseases and related immune conditions.
• CDX‑622 (example program name): an immuno‑oncology or immunomodulatory agent designed for specific tumor or inflammatory indications.

Each program is described in company materials with its mechanism of action, targeted indication(s) and current clinical stage. Development stages range from preclinical to Phase 2 or later, depending on the candidate and recent trial readouts.

R&D strategy notes:

• Focused clinical development: concentrate resources on programs with the most promising safety/efficacy signals.
• Selective partnering: potential collaborations for commercialization or late‑stage development where appropriate.
• Adaptive design and biomarker use: modern trial approaches to enrich responder populations and accelerate decision points.

Because clinical outcomes drive long‑term value for cldx stock, monitoring trial updates, safety data and regulatory interactions is essential.

Financial summary

Celldex, like most clinical‑stage biotech companies, generally reports limited or no commercial revenues and operates at a net loss while funding R&D and trials. Primary financial attributes investors monitor include cash and cash equivalents (runway), operating expenses and sources of financing.

Broad financial themes for cldx stock holders:

• Revenue composition: historically minimal product revenue; most reported revenue (if any) may be from collaborations or licensing fees.
• Profitability: typically operating losses as R&D and SG&A expenses exceed any early revenue.
• Balance sheet: cash position and short‑term investments are critical to assess runway until the next financing need or value‑creating event.

As of Jan 28, 2026, company financials and specific figures should be verified directly in the latest SEC Form 10‑Q or 10‑K filings and reported summaries available from major financial portals.

Recent financial results

Public quarterly and annual reports provide the most authoritative updates. Recent reporting cycles generally emphasize:

• Quarterly operating losses driven by R&D spend and trial activity.
• Cash burn and projected runway disclosed by management.
• Any milestone or collaboration payments recognized as revenue in the reporting period.

Investors tracking cldx stock should consult the latest 10‑Q and 10‑K and listen to investor presentations or earnings calls for management’s runway guidance and capital plan.

Stock market information

• Ticker symbol: CLDX
• Exchange: NASDAQ
• Sector: Biotechnology
• Primary identifiers: ISIN and exchange codes appear on financial portals and brokerage platforms

Shares outstanding, float and market capitalization change with issuance events and share price. For active trading and position sizing, use real‑time quotes and the company’s latest shares‑outstanding disclosures.

Historical price and performance

CLDX has historically shown volatility consistent with small‑ and mid‑cap biotech stocks, where single trial readouts or regulatory news can drive large price moves. Commonly reported metrics include:

• 52‑week high/low ranges quoted on financial portals
• Multi‑period returns (YTD, 1‑year, 3‑year) reflecting clinical and company news

As of Jan 28, 2026, summaries from market data providers and stock pages provide specific 52‑week ranges and historical charts. Investors should examine charts and returns on their trading platform or Bitget market tools for up‑to‑the‑minute graphs and percent performance.

Trading data and liquidity

Liquidity indicators for cldx stock include average daily volume, recent volume spikes, bid‑ask spreads and option market activity (if listed). Biotech tickers often exhibit:

• Periods of low liquidity interspersed with high volume around trial news
• Elevated volatility measures compared to large‑cap equities
• Short interest that can amplify price moves during news events

Market data aggregators and broker platforms provide volume and volatility statistics. For trading, consider using limit orders and monitoring premarket/premarket notices because significant moves can occur outside regular trading hours.

Analyst coverage and investor sentiment

CLDX is followed by sell‑side analysts and independent research outlets that publish coverage, ratings and price targets. Consensus tables on financial portals aggregate buy/hold/sell ratings and target ranges. Analyst coverage for cldx stock can change with the cadence of clinical milestones: coverage often intensifies before or after key readouts and may decline during quiet periods.

Investor sentiment is shaped by:

• Clinical trial updates and safety/efficacy data
• Cash runway disclosures and financing activity
• Any partnerships, licensing deals or corporate transactions

Always interpret analyst notes and targets as commentary, not prescriptions; they reflect assumptions about clinical success, timelines and commercialization potential.

Ownership and shareholders

Major institutional holders and insider ownership levels are disclosed in regulatory filings and aggregated by market data services. Typical ownership patterns for clinical‑stage biotech companies include:

• Institutional investors holding concentrated positions via funds focused on healthcare/biotech
• Insider ownership (management, board) that may represent single‑digit to low double‑digit percentages depending on company history
• Potential inclusion in small‑cap or biotech‑focused ETFs if criteria are met

Tracking changes in institutional holdings and insider transactions can give insight into perceived company prospects but should be considered alongside fundamental and clinical developments.

Corporate governance and management

Effective governance and experienced management are important for clinical execution. Relevant governance topics for cldx stock include:

• Executive leadership: CEO and key scientific officers with track records in drug development
• Board composition: oversight experience, relevant scientific and commercial expertise
• Governance practices: audit and compensation committees, disclosure practices and shareholder communications

Material leadership changes (CEO transition, C‑suite turnover) are typically announced via press releases and filed with the SEC; these events can influence investor perception of operational stability.

Regulatory filings and reporting

Primary sources for authoritative information on Celldex include the company’s SEC filings (Form 10‑K annual reports, Form 10‑Q quarterly reports, Form 8‑K for material events) and investor presentations. Investors tracking cldx stock should:

• Review the latest 10‑Q/10‑K for financial statements and risk factor updates
• Check Form 8‑K filings for material events such as trial updates, financings or leadership changes
• Use investor relations materials for presentation slides and conference call transcripts

As of Jan 28, 2026, these filings remain the official record for historical performance and mandated disclosures.

Recent news and events

Biotech stocks like cldx stock move on a combination of clinical readouts, regulatory decisions, partnership announcements and financing news. Typical recent event types that affect share price include:

• Clinical trial results or interim data releases
• Regulatory interactions (e.g., requests for additional data, designations such as Fast Track)
• Financing transactions (public offerings, private placements, convertible notes)
• Licensing or co‑development agreements
• Presentation at scientific or investor conferences

As of Jan 28, 2026, financial portals and company press releases are primary sources for these updates. For example, market‑facing summaries and charts from major business news providers update price reaction after clinical announcements. When a trial readout is published, expect immediate market reactions reflected in intraday volume and price volatility.

Investment considerations and risks

This section outlines common, factual considerations investors typically weigh when assessing cldx stock. The tone is neutral and does not constitute investment advice.

Primary factors:

• Clinical and regulatory risk: Success in early‑phase trials does not guarantee approval; efficacy and safety outcomes are uncertain.
• Financing and cash runway risk: Clinical development requires capital; companies may issue equity or debt, diluting existing shareholders or altering capital structure.
• Competitive landscape: Multiple companies may target similar mechanisms or indications, affecting future commercial potential.
• Biotech sector volatility: Small‑cap biotech stocks often experience sharp moves around news; liquidity can amplify price swings.
• Execution risk: Management’s ability to run trials, manage CROs and meet timelines affects milestones and costs.

For cldx stock specifically, the main sources of value (and risk) are the clinical milestones of lead candidates and the company’s ability to fund operations through key development stages.

See also

• Biotechnology sector overview
• Clinical trial phases (I, II, III) and endpoints
• Antibody therapeutics and bispecific formats
• NASDAQ small‑cap and mid‑cap market dynamics

References

Note: The summary below references widely used financial and regulatory sources for factual data and filings. For the most current and quantifiable figures (market cap, share count, 52‑week ranges, cash balances), consult the cited sources directly and the company’s SEC filings.

• Markets Insider / Business Insider — CLDX stock page (market data and quotes)
• StockLight — CLDX profile (company snapshot)
• GuruFocus — CLDX company summary and financial metrics
• MSN Money — CLDX stock details and charts
• Reuters / LSEG — CLDX charts and market news
• Finviz — CLDX quote and screening metrics
• Nasdaq — CLDX real‑time quotes, financials and historical data
• SEC filings (Form 10‑Q, 10‑K, 8‑K) — official company financial and material disclosures

As of Jan 28, 2026, according to the financial portals and the company’s public filings, cldx stock remains a clinical‑stage biotech equity with development risk and event‑driven dynamics. For the latest numeric indicators such as market capitalization and average daily volume, refer to Nasdaq or your trading platform.

Further exploration: track cldx stock performance and filings using Bitget’s market watchlists and educational resources. Use Bitget Wallet for secure portfolio tracking and Bitget’s market tools to monitor intraday activity and historical charts.

Explore more on research pages and check the latest SEC filings before making any decisions related to exposure to biotech equities.

As of Jan 28, 2026, the descriptions above summarize publicly available information from the referenced market trackers and regulatory filings. Specific numeric data points (e.g., exact market cap, shares outstanding, 52‑week high/low) should be verified in the latest filings or on market data platforms before relying on them for analysis.